Neurology
Apitegromab Adds Muscle-Directed Therapy in SMA Care
The FDA approved apitegromab for patients aged 2 years or older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment.
Rayan Salih · September 23, 2026 · 7 min